INTERVENTION 1:	Intervention	0
Ixabepilone 16 mg/m^2	Intervention	1
ixabepilone	CHEBI:63605	0-11
ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest	Intervention	2
ixabepilone	CHEBI:63605	0-11
week	UO:0000034	22-26
week	UO:0000034	35-39
week	UO:0000034	55-59
INTERVENTION 2:	Intervention	3
Ixabepilone 40 mg/m^2	Intervention	4
ixabepilone	CHEBI:63605	0-11
ixabepilone 40 mg/m^2 every 3 weeks	Intervention	5
ixabepilone	CHEBI:63605	0-11
Inclusion Criteria:	Eligibility	0
Has MBC that is measurable by RECIST or has nonmeasurable disease with serum CA27.29 (or CA15.3)  50	Eligibility	1
disease	DOID:4,OGMS:0000031	58-65
Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer	Eligibility	2
growth factor	BAO:0002024	20-33
receptor	BAO:0000281	34-42
breast cancer	DOID:1612	61-74
Prior chemotherapy is permitted with no limit on the number of prior regimens	Eligibility	3
Two weeks or more have elapsed since last chemotherapy or radiation treatment	Eligibility	4
Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2	Eligibility	5
group	CHEBI:24433	36-41
Is female,  18 yrs of age	Eligibility	6
female	PATO:0000383	3-9
age	PATO:0000011	22-25
Protocol defined appropriate laboratory values	Eligibility	7
Negative pregnancy test within 7 calendar days prior to registration	Eligibility	8
Has signed a patient informed consent	Eligibility	9
patient	HADO:0000008,OAE:0001817	13-20
Exclusion Criteria:	Eligibility	10
Had prior treatment with ixabepilone or other epothilones	Eligibility	11
ixabepilone	CHEBI:63605	25-36
Has HER2+ disease	Eligibility	12
disease	DOID:4,OGMS:0000031	10-17
Has a known, prior, severe (National Cancer Institute Common Terminology Criteria Adverse Events [NCI CTCAE] Grade 3-4) history of hypersensitivity reaction to a drug formulated in Cremophor Â® EL (polyoxyethylated castor oil)	Eligibility	13
severe	HP:0012828	20-26
cancer	DOID:162	37-43
history	BFO:0000182	120-127
hypersensitivity	GO:0002524,DOID:1205	131-147
drug	CHEBI:23888	162-166
castor oil	CHEBI:140618	214-224
Is receiving concurrent immunotherapy, hormonal therapy or radiation therapy	Eligibility	14
Is receiving concurrent investigational therapy or has received such therapy within the past 30 days	Eligibility	15
Has peripheral neuropathy > Grade 1	Eligibility	16
peripheral neuropathy	HP:0009830,DOID:870	4-25
Has evidence of central nervous system (CNS) involvement requiring radiation or steroid treatment. Participants with stable brain metastases who are off steroids at least 2 weeks are eligible	Eligibility	17
central nervous system	UBERON:0001017	16-38
steroid	CHEBI:35341	80-87
steroid	CHEBI:35341	153-160
stable	HP:0031915	117-123
brain	UBERON:0000955	124-129
Is pregnant or breast feeding	Eligibility	18
breast	UBERON:0000310	15-21
Outcome Measurement:	Results	0
Progression-Free Survival (PFS) at 6 Months (6-month PFS Rate): Proportion of Participants Progression Free at 6 Months	Results	1
rate	BAO:0080019	57-61
PFS at 6 months was defined as proportion of participants who neither progressed nor died before 6 months. Computed using Kaplan-Meier estimates.	Results	2
Time frame: From the date of randomization to 6-months on study	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Ixabepilone 16 mg/m^2	Results	5
ixabepilone	CHEBI:63605	17-28
Arm/Group Description: ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest	Results	6
ixabepilone	CHEBI:63605	23-34
week	UO:0000034	45-49
week	UO:0000034	58-62
week	UO:0000034	78-82
Overall Number of Participants Analyzed: 85	Results	7
Measure Type: Number	Results	8
Unit of Measure: Percentage of Participants  28.6        (18.9 to 38.9)	Results	9
Results 2:	Results	10
Arm/Group Title: Ixabepilone 40 mg/m^2	Results	11
ixabepilone	CHEBI:63605	17-28
Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks	Results	12
ixabepilone	CHEBI:63605	23-34
Overall Number of Participants Analyzed: 91	Results	13
Measure Type: Number	Results	14
Unit of Measure: Percentage of Participants  42.7        (31.5 to 53.5)	Results	15
Adverse Events 1:	Adverse Events	0
Total: 25/82 (30.49%)	Adverse Events	1
neutropenia 1/82 (1.22%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	0-11
anemia 1/82 (1.22%)	Adverse Events	3
anemia	HP:0001903,DOID:2355	0-6
thrombocytopenia 1/82 (1.22%)	Adverse Events	4
thrombocytopenia	HP:0001873,DOID:1588	0-16
febrile neutropenia 0/82 (0.00%)	Adverse Events	5
neutropenia	HP:0001875,DOID:1227	8-19
tachycardia 3/82 (3.66%)	Adverse Events	6
tachycardia	HP:0001649	0-11
fibrillation atrial 0/82 (0.00%)	Adverse Events	7
supraventricular tachycardia 1/82 (1.22%)	Adverse Events	8
supraventricular tachycardia	HP:0004755	0-28
ventricular tachycardia 1/82 (1.22%)	Adverse Events	9
ventricular tachycardia	HP:0004756	0-23
angina attack 0/82 (0.00%)	Adverse Events	10
congestive heart failure 0/82 (0.00%)	Adverse Events	11
congestive heart failure	HP:0001635,DOID:6000	0-24
flutter atrial 0/82 (0.00%)	Adverse Events	12
Adverse Events 2:	Adverse Events	13
Total: 30/89 (33.71%)	Adverse Events	14
neutropenia 5/89 (5.62%)	Adverse Events	15
neutropenia	HP:0001875,DOID:1227	0-11
anemia 1/89 (1.12%)	Adverse Events	16
anemia	HP:0001903,DOID:2355	0-6
thrombocytopenia 1/89 (1.12%)	Adverse Events	17
thrombocytopenia	HP:0001873,DOID:1588	0-16
febrile neutropenia 2/89 (2.25%)	Adverse Events	18
neutropenia	HP:0001875,DOID:1227	8-19
tachycardia 1/89 (1.12%)	Adverse Events	19
tachycardia	HP:0001649	0-11
fibrillation atrial 1/89 (1.12%)	Adverse Events	20
supraventricular tachycardia 0/89 (0.00%)	Adverse Events	21
supraventricular tachycardia	HP:0004755	0-28
ventricular tachycardia 0/89 (0.00%)	Adverse Events	22
ventricular tachycardia	HP:0004756	0-23
angina attack 1/89 (1.12%)	Adverse Events	23
congestive heart failure 1/89 (1.12%)	Adverse Events	24
congestive heart failure	HP:0001635,DOID:6000	0-24
flutter atrial 1/89 (1.12%)	Adverse Events	25
